Sophia GeneticsSOPH +0.97%72 Gross Margin % is 68.01% as of Mar. 2026, which is 1% above its 10-year median of 67.40. GuruFocus rates SOPH with a GF Score™ of 72/100 and a GF Value™ of $5.03 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 631 Healthcare Providers & Services companies, Sophia Genetics ranks better than 75.91% on this metric.
The historical rank and industry rank for Sophia Genetics's Gross Margin % or its related term are showing as below:
SOPH'
s Gross Margin % Range Over the Past 10 Years
Min: 62.29 Med: 67.4 Max: 70.3
Current: 67.28
During the past 8 years, the highestGross Margin % of Sophia Genetics was 70.30%. The lowest was 62.29%. And the median was 67.40%.
SOPH's Gross Margin % is ranked better than 75.91% of 631
companies
in the Healthcare Providers & Services industry
Industry Median: 40.09
vs SOPH: 67.28
Sophia Genetics had a gross margin of 68.01% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Sophia Genetics was 2.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Sophia Genetics had a gross margin of 68.01% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Sophia Genetics Gross Margin % Related Terms
Sophia Genetics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Sophia Genetics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SOPH vs SLP, TBRG, CARL: Gross Margin % Comparison
For the Health Information Services subindustry, Sophia Genetics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sophia Genetics Gross Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sophia Genetics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Sophia Genetics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Sophia Genetics (SOPH) has a Gross Margin % of 68.01% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Sophia Genetics and its competitors. This is near median its historical median of 67.40. Over the past decade, Sophia Genetics' Gross Margin % has ranged from 62.29 to 70.30. According to the industry distribution chart, Sophia Genetics ranks #152 out of 631 companies in the Healthcare Providers & Services industry, placing it in the top 24.1%.
Is Sophia Genetics' Gross Margin % too high?
Sophia Genetics' current Gross Margin % of 68.01% is near median its 10-year median of 67.40. Over the past 10 years, this metric has ranged from a low of 62.29 to a high of 70.30. The Healthcare Providers & Services industry median Gross Margin % is 40.09. Sophia Genetics' value of 68.01% is 69.6% above this industry median. Based on the distribution chart, Sophia Genetics ranks #152 out of 631 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Sophia Genetics has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sophia Genetics' Gross Margin % compare to SLP and TBRG?
According to the Healthcare Providers & Services industry distribution chart, Sophia Genetics ranks #152 out of 631 companies for Gross Margin %. This places Sophia Genetics in the top 24% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 40.09. Sophia Genetics' value of 68.01% is 69.6% above this benchmark. Historically, Sophia Genetics' own Gross Margin % has ranged from 62.29 to 70.30 over the past decade. While the company's 10-year median is 67.40 vs. the industry median of 40.09, Sophia Genetics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Healthcare Providers & Services company?
The median Gross Margin % among Healthcare Providers & Services companies is 40.09, based on 631 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sophia Genetics's current Gross Margin % of 68.01% is 69.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Sophia Genetics and its competitors. For the Healthcare Providers & Services industry, the median Gross Margin % is 40.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sophia Genetics's current Gross Margin % is 68.01%, which is near median its own 10-year median of 67.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sophia Genetics stock overvalued right now?
Based on GuruFocus' analysis, Sophia Genetics (SOPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.03, compared to a current price of $5.75 — trading 14.3% above its estimated fair value. The current Gross Margin % is 68.01%, which is near median its 10-year median of 67.40 and 69.6% above the Healthcare Providers & Services industry median of 40.09. Sophia Genetics' overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Sophia Genetics (SOPH), the current Gross Margin % is 68.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sophia Genetics (SOPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sophia Genetics stock appears to be overvalued.
The current stock price of $5.75 is trading 14.3% above its estimated GF Value™ of $5.03.
GuruFocus considers Sophia Genetics to be Modestly Overvalued.
Key valuation signals for SOPH:
Gross Margin %: 68.01% (near median its 10-year median of 67.40)
GF Value™: $5.03 vs. price of $5.75 (14.3% above fair value)
Industry Position: 69.6% above the Healthcare Providers & Services median (#152 of 631)
No single metric tells the full story. See the SOPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
72GF Score
Get the complete analysis for SOPH
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SOPH has been successfully added to your 
